Biotech News

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

Taysha Gene Therapies (TSHA)Taysha Gene TherapiesCompany update

DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today

Related news

TSHATaysha Gene Therapies2026-11-12 12:30 EST

Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update

TSHATaysha Gene Therapies2026-11-06 13:00 EST

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CRBUCaribou2026-11-04 14:00 EST

Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting

CRSPCRISPR Therapeutics2026-11-04 14:01 EST

CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition

EDITEditas Medicine2026-10-14 13:00 EST

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

MGTXMeiraGTx2026-10-27 12:00 EST

MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting

HRMYHarmony Biosciences2026-11-04 12:30 EST

Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile

TEVATeva Pharmaceutical Industries2026-10-02 12:00 EST

Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients

SRPTSarepta Therapeutics2026-09-25 12:30 EST

Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress

ANNXAnnexon, Inc.2026-09-24 12:00 EST

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

Taysha Gene Therapies

CNS Gene Therapy Focus Taysha Gene Therapies develops adeno-associated virus gene therapies for severe monogenic diseases of the central nervous system. Its strategy centers on one-time treatments intended to address the underlying genetic cause of disease. Lead Rett Syndrome Program TSHA-102 is an intrathecally delivered AAV9 gene...

Recent company news

Stock data

Close
3.77 USD
Market cap
1.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States